<img height="1" width="1" style="display:none" src="https://www.facebook.com/tr?id=780280282443813&amp;ev=PageView&amp;noscript=1">
search

    Albireo Pharma, Inc.

    verified_userVerify Profile
    Companies » Health Care » Pharmaceuticals & Biotechnology » Pharmaceuticals

    About Albireo Pharma, Inc.

    Albireo is a clinical-stage biopharmaceutical company focused on the development and potential commercialization of novel bile acid modulators to treat orphan pediatric liver diseases and other liver or gastrointestinal diseases and disorders. We have deep expertise in bile acid biology and a pipeline of clinical and nonclinical programs. Our parent company, Albireo Pharma, Inc., is located in Boston, Massachusetts and our key operating subsidiary, Albireo AB, is located in Gothenburg, Sweden. We were spun out from AstraZeneca in 2008. Source

    At A Glance

    • CAPITAL RAISE STATUS
      Not Currently Raising
    • FILING TYPE
      Public
    • PLATFORM TYPE
      NASDAQ
    • RAISED AMOUNT
      $X,XXX,XXX
    • PRE-MONEY EVAULATION
      $X,XXX,XXX
    • SIC CODE
      2834
    • NIN CODE
      ####
    • LEADERSHIP
      Ron Cooper
    • FOUNDED
      2003
    • EMPLOYEES
      20
    • SECTOR
      Pharmaceuticals & Biotechnology
    • SUBSECTOR
      Pharmaceuticals

    Company Tags

    No articles found.

    Quotient Limited

    Quotient Limited

    We are an established, commercial-stage diagnostics company committed to reducing ...

    We are an established, commercial-stage diagnos...

    Filing Type:    PU
    Sonoma Pharmaceuticals, Inc.

    Sonoma Pharmaceuticals, Inc.

    Sonoma Pharmaceuticals is a specialty pharmaceutical company that develops and mar...

    Sonoma Pharmaceuticals is a specialty pharmaceu...

    Filing Type:    PU
    MedChain Inc

    MedChain Inc

    MedChain's mission is to use blockchain technology to establish a better, more sec...

    MedChain's mission is to use blockchain technol...

    Amount Raised:    $466,896.00
    Fundraising Status:    EC
    Filing Type:    CF
    SIGA Technologies Inc.

    SIGA Technologies Inc.

    SIGA Technologies, Inc. is a public, commercial-stage pharmaceutical company focus...

    SIGA Technologies, Inc. is a public, commercial...

    Filing Type:    PU
    Chimerix, Inc.

    Chimerix, Inc.

    Chimerix is a development-stage biopharmaceutical company dedicated to acceleratin...

    Chimerix is a development-stage biopharmaceutic...

    Filing Type:    PU
    Cytokinetics, Incorporated

    Cytokinetics, Incorporated

    Cytokinetics is a late-stage biopharmaceutical company focused on discovering, dev...

    Cytokinetics is a late-stage biopharmaceutical ...

    Filing Type:    PU
    GENFIT S.A.

    GENFIT S.A.

    GENFIT is a late-stage biopharmaceutical company dedicated to the discovery and de...

    GENFIT is a late-stage biopharmaceutical compan...

    Filing Type:    PU
    Galmed Pharmaceuticals Ltd.

    Galmed Pharmaceuticals Ltd.

    Galmed is a clinical-stage biopharmaceutical company focused on the development of...

    Galmed is a clinical-stage biopharmaceutical co...

    Filing Type:    PU
    Intercept Pharmaceuticals, Inc.

    Intercept Pharmaceuticals, Inc.

    Intercept is a biopharmaceutical company focused on the development and commercial...

    Intercept is a biopharmaceutical company focuse...

    Filing Type:    PU
    Redhill Biopharma Ltd.

    Redhill Biopharma Ltd.

    RedHill Biopharma Ltd. (NASDAQ: RDHL) (Tel-Aviv Stock Exchange: RDHL) is a special...

    RedHill Biopharma Ltd. (NASDAQ: RDHL) (Tel-Aviv...

    Filing Type:    PU
    Edesa Biotech, Inc.

    Edesa Biotech, Inc.

    Edesa Biotech Inc. is a clinical-stage biopharmaceutical company founded by expert...

    Edesa Biotech Inc. is a clinical-stage biopharm...

    Filing Type:    PU
    Seres Therapeutics, Inc.

    Seres Therapeutics, Inc.

    Seres Therapeutics, Inc. is a microbiome therapeutics platform company developing ...

    Seres Therapeutics, Inc. is a microbiome therap...

    Filing Type:    PU
    ©2026 National Investor Network. All Rights Reserved.